Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 25,750 shares at $32.58 ($839K) on 2025-03-06, disclosed to the SEC on 2025-03-10.
Scheduled sale ($839k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.58 | 12,875 | $419K | 50.0% |
| 2 | $32.58 | 12,875 | $419K | 50.0% |
| Total | $32.58 avg | 25,750 | $839K | 100% |
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |